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Purpose: To identify the mutation in the fibrillin-1 gene (FBN1) in a Chinese family with Marfan syndrome (MFS).
Methods: Patients and family members were given complete physical, ophthalmic, and cardiovascular examinations.
Genomic DNA was extracted from leukocytes of venous blood of six individuals in the family and 170 healthy Chinese
individuals. All of the 65 coding exons and their flanking intronic boundaries of FBN1 were amplified in the proband by
polymerase chain reaction and followed by direct sequencing. The mutation identified in the proband was screened in the
other family members and the 170 healthy Chinese individuals by direct sequencing. Protein conservation analysis was
performed in six species using an online ClustalW tool. Protein structure was modeled based on the Protein data bank and
mutated in DeepView v4.0.1 to predict the functional consequences of the mutation.
Results: A novel heterozygous c.3703T>C change in exon 29 of FBN1 was detected in the proband, which resulted in
the substitution of serine by proline at codon 1235 (p.S1235P). This mutation was also present in two family members
but absent in the other, unaffected family members and the 170 healthy Chinese individuals. The mutant residue located
in the calcium binding epidermal growth factor-like#15 domain is highly conserved among mammalian species and could
probably induce conformation change of the domain.
Conclusions: We indentified a novel p.S1235P mutation in FBN1, which is the causative mutation for MFS in this family.
Our result expands the mutation spectrum of FBN1 and contributes to the study of the molecular pathogenesis of Marfan
syndrome.
Marfan syndrome (MFS, OMIM 154700) is a relatively
common  autosomal  dominant  hereditary  disorder  of  the
connective  tissue,  with  prominent  manifestations  in  the
skeletal, ocular, and cardiovascular systems [1]. It is clinically
diagnosed according to the Ghent criteria [2].
MFS  is  mainly  caused  by  mutations  in  the  human
fibrillin-1 (FBN1) gene [3]. FBN1 contains 65 exons encoding
a secreted 350 kDa glycoprotein, which is highly conserved
among different species [4]. Fibrillin-1 is characterized by a
specific module organization in the extracellular matrix and
is mainly composed of three types of repeated modules: 47
epidermal  growth  factor  (EGF)-like  modules  (43  calcium
binding [or cb] EGF-like modules and 4 non-cb EGF-like
modules),  7  transforming  growth  factor-binding  (or  TB)
protein-like modules (8 Cys/TB), and 2 hybrid modules [5].
To date, more than 60% of the reported mutations of FBN1
are missense mutations, and the majority of these are located
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in  the  cb  EGF  modules  (in  particular,  cysteine  residues,
implicated  in  disulfide  bond  formation,  or  other  residues
implicated  in  calcium-binding  and/or  intra-/intermolecular
interactions) [6,7]. There is limited evidence of genotype-
phenotype  correlations  of  this  disorder,  while  mutations
associated with neonatal MFS and other severe forms have
been  shown  to  cluster  in  exons  24–32  [8-11].  Molecular
analysis  of  FBN1  is  necessary  because  such  analysis  can
detect  at-risk  individuals  at  an  early  stage  and  offer  the
possibility of prenatal diagnosis.
We came across a four-generation family affected with
MFS in Northeast China and detected a novel heterozygous
mutation in FBN1. The mutation was found in the affected
individuals but was not observed in any of the healthy family
members.
METHODS
Patients and clinical data: The proband, a 32-year-old female,
was diagnosed with MFS according to the Ghent criteria [2].
The family history revealed four affected members over four
generations,  two  of  whom  were  deceased.  Available
individuals II:2, II:6, II:7, III:4, III:12, and IV:4 were given
complete  physical,  ophthalmic,  and  cardiovascular
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2421examinations after obtaining informed consent (Figure 1).
One hundred Chinese controls without diagnostic features of
MFS were also recruited. The study was approved by the
Harbin  Medical  University  Ethics  Committee  (Harbin,
China).
Genomic DNA preparation: Whole blood from six members
of the family (II:2, II:6, II:7, III:4, III:12, and IV:4) and 170
unrelated Chinese controls were collected in tubes containing
EDTA  as  an  anticoagulant.  Genomic  DNA  was  extracted
using a TIANamp Blood DNA Kit (Tiangen Biltech Co. Ltd,
Beijing, China) according to the manufacturer’s protocol.
Mutation  screening:  All  65  coding  exons  and  flanking
intronic  regions,  including  splice  sites  of  FBN1,  were
amplified by polymerase chain reaction (PCR) using a set of
primers listed in Appendix 1. PCR was performed for 35
cycles, with a denaturing phase of 30 s at 94 °C, annealing
phase of 30 s at 58–62 °C, and an extension of 1 min at 72 °C.
The PCR products were subsequently purified with a TIANgel
Midi  Purification  Kit  (Tiangen  Biltech  Co.  Ltd)  and
sequenced with an ABI 3130XL Genetic Analyzer (Applied
Biosystems,  Foster  City,  CA).  Sequencing  results  were
assembled  and  analyzed  using  Chromas  2.22  software
(Technelysium  Pty.  Ltd.,  QLD,  Australia)  with  reference
sequence in the Universal Mutation Database (UMD).
Protein structure analysis: A schematic of the cb EGF-like
domain of human fibrillin-1 was used to assess the possible
impact of the mutation at the secondary structure level [12].
A homology 3D model of the cb EGF-like#15 domain was
created based on the Protein data bank (PDB) template 1LMJ
[13] (45% sequence identity). DeepView v4.0.1 was used to
display  the  structure  file  and  to  predict  the  potential
consequence of the mutation [14].
RESULTS
Clinical findings: Two members (II:2 and III:12) of the family
showed classic MFS (Appendix 2), and the unaffected family
members, including a spouse (II:6), appeared normal. The
daughter of the proband (IV:4), who was 2 years old, was too
young for a clinical diagnosis to be made because several
manifestations of MFS are age-dependent and may not yet be
present  in  childhood.  The  proband  had  bilateral  lens
dislocation (Figure 2A,B), high myopia, and strabismus of
both  eyes.  Echocardiography  revealed  cardiovascular
manifestation of dilatation of the aortic root and mild mitral
valve prolapse in the proband. Skeletal system abnormalities
such  as  tall  stature,  long  limbs,  joint  hypermobility,  long
narrow  head,  and  arachnodactyly  (Figure  2C),  were  also
present in the proband. Individual II:2 showed similar clinical
symptoms as the proband, with the exception of abnormalities
of the cardiovascular system. Lentectomy and intraocular lens
implantation  were  performed  on  individual  II:2  in  2010.
Family member II:5 had died of heart disease at the age of 53
and III:2 had died of hepatic cancer at the age of 39, and
according to the proband’s description, both of them appeared
with tall stature, long limbs, and poor vision.
Mutation analysis: Direct sequencing of FBN1 revealed a
novel heterozygous mutation, c.3703T>C in exon 29, which
Figure 1. The pedigree of the family.
Squares and circles indicate males and
females, respectively, and the darkened
symbols  represent  the  affected
members. Slashed symbols denote that
the subject is deceased. Symbols with a
question mark in the center indicate that
the  member  is  not  diagnosed  clearly.
Asterisks  indicate  the  subjects
participating in this study. The patient
indicated by the arrow is the proband.
Figure 2. Photographs of the proband.
A  and  B  display  the  slit  lamp
photographs of both of the proband’s
eyes  after  the  pupils  were  dilated,
showing ectopia lentis. In the right eye
(A), the lens is dislocated nasally. In the
left  eye  (B),  the  lens  is  dislocated
superonasally. C shows arachnodactyly
of the proband.
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2422resulted in the substitution of serine by proline (p.S1235P;
Figure 3A). The mutation identified in the proband was also
found in patient II:2 and the available affected member IV:4
(Figure 3B,C). No mutation was detected in the healthy family
members (Figure 3D-F) or in any of the 170 unrelated control
subjects (Figure 3G).
Potential  functional  consequences  of  the  mutation:  The
missense mutation c.3703T>C resulted in the substitution of
serine at codon 1235, which is located in the neonatal region
of fibrillin-1 (Figure 4A), and is highly conserved among
mammalian species (Figure 3H). Secondary structure analysis
of  the  cb  EGF-like  domain  revealed  that  the  mutant
proline1235 could neither interfere with calcium binding in the
NH2-terminal region of the domain nor influence disulfide
bond  formation  [15,16]  (Figure  4B).  Prediction  by
DeepView v4.0.1 suggested that the mutant residue could
probably induce steric clash with its surroundings. Therefore,
the conformation of the cb EGF-like domain was likely to be
altered by the presence of this mutation (Figure 4C,D).
DISCUSSION
In  this  study,  we  identified  a  novel  heterozygous  FBN1
mutation (p.S1235P) in a four-generation family affected with
MFS. This missense mutation is located in the cb EGF-like#15
domain.
It is clear that EGF-like domains play a major role in the
pathogenesis of fibrillinopathies, as most of the mutations in
these domains are associated with classic MFS [17]. Each cb
Figure  3.  A  novel  FBN1  mutation  in
exon 29. A-C show a heterozygous T>C
transition  (indicated  by  the  arrow)
resulting in the substitution of serine by
proline (S1235P) in the proband, patient
II:2, and the proband’s daughter, IV:4,
respectively.  D-F  show  the
corresponding  normal  sequence  in
unaffected family members II:7 and III:
4 and spouse II:6, respectively. G shows
the corresponding normal sequence in a
healthy  member.  H  displays  the
sequence alignment of FBN1 orthologs
surrounding  the  mutated  site  using
ClustalW. The serine1235 of the human
FBN1  protein  is  highly  conserved  in
several species. These sequences were
selected from the NCBI database.
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2423EGF-like domain of fibrillin-1 contains six highly conserved
cysteine  residues  that  form  three  intra-domain  disulphide
bonds (C1-C3, C2-C4, C5-C6) and a consensus sequence for
calcium  binding  in  the  NH2-terminal  region  [15,16].  The
mutant residue found in our study, located at the 39th residue
of the cb EGF-like#15 domain, did not affect disulphide bond
formation or calcium binding of the domain at the secondary
structure level. 3D structure analysis by DeepView v4.0.1
showed  that  the  substitution  of  serine  by  proline  could
probably  induce  steric  clash  with  its  surroundings,  which
probably  resulted  in  a  conformation  change  and  had  a
predictable detrimental effect on its function. It is evident that
the structural effects of different FBN1 missense mutations
are complex [18]. Mutations in cb EGF motifs not affecting
cysteines  or  residues  of  the  calcium  binding  consensus
sequence are extremely rare and have been postulated to affect
intramolecular  packing  or  intermolecular  interactions,  and
subsequently  affect  microfiber  assembly  [13].  Previously,
only 6 mutations were published in the UMD website in the
cb EGF-like#15 domain, and none of those mutations affected
the residues between C-5 and C-6 [7,19-21]. The present study
not only suggested that residues between C-5 and C-6 of cb
EGF-like domains play an important role in maintaining the
function of the FBN1 protein, but also added a new case to the
notion that cb EGF-like#14–18 domains (in exons 28–32) are
functionally more essential in fibrillin-1 of classic MFS than
that of neonatal MFS [22]. This rare mutation found in our
study is located in the hot spot region for neonatal MFS and
could also cause classic MFS. There is general consensus that
neither the location of the affected module in the protein nor
the position of the mutant residue is, by itself, sufficient to
predict potential genotype-phenotype correlations [23].
This missense mutation was also found in the proband’s
daughter, who was 2 years old and did not yet fulfill the
diagnostic  criteria.  As  such,  in  situations  of  clinical
uncertainty, molecular analysis of FBN1 seems a logical aid
in the clinical diagnosis of MFS [18]. Moreover, the most
important complication of MFS is a progressive dilatation of
the aortic root and ascending aorta, leading to aortic valve
incompetence and aortic dissection [24]. As a result, early
Figure 4. Structure analyses of the missense mutation in the calcium binding (cb) epidermal growth factor (EGF)-like#15 domain. A displays
the location of the affected module in the neonatal region of the fibrillin-1 domain structure. B displays the consensus secondary structure of
a prototypical cb EGF-like domain. Calcium binding in the NH2-terminal region of the wild-type domain is mediated by the consensus sequence
(D/N)-X-(D/N)(E/Q)Xm(D/N)Xn(Y/F) (m and n are variables), and highly conserved amino acids are identified by their single-letter amino
acid code. Letter C in the schematic represents the highly conserved cysteines of cb EGF-like domain, and the lines between cysteines represent
disulfide bridges. The mutation S1235P is located at the 39th residue of the domain, which neither interferes with calcium binding of the
domain nor influences disulfide bond formation. C displays the 3D structure of the cb EGF-like#15 domain, which is created based on the
Protein data bank (PDB) template 1LMJ (45% sequence identity) by DeepView v4.0.1. The yellow lines represent disulfide bonds, and the
purple residue represents the unaffected serine. D displays the potential consequence of the mutation. The purple residue represents the
substitute proline, and the purple dashed lines mean steric clash with surroundings, which may lead to unstable conformation.
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2424recognition  of  at-risk  individuals  not  (yet)  fulfilling  the
diagnostic criteria by molecular diagnosis is important in view
of the available treatments that can significantly improve life
expectancy and also offer the possibility of prenatal diagnosis.
Although the four-generation MFS family we studied was
large, the number of patients was relatively small. For genetic
studies, it is better to examine pedigrees with more affected
individuals, because (1) to find the mutant gene and exclude
genetic heterogeneity, linkage analysis for candidate gene
screening  should  be  initially  done,  and  in  this  condition,
numbers of affected individuals should be large enough; and
(2) more patients can help investigators to better interpret the
rule of inheritance of the disease and display the genotype-
phenotype correlations.
Collectively, evidences from our study and published
data  supported  that  this  novel  p.S1235P  mutation  is  the
causative mutation for MFS in this four-generation family.
Mutations in cb EGF-like domains of FBN1 play a critical role
in the pathogenesis of classic MFS, and molecular diagnosis
of MFS is becoming more and more important. Although
more than 600 FBN1 mutations have been published in the
UMD website for MFS, information on genotype–phenotype
correlations  is  still  limited,  especially  in  the  Chinese
population. Our data adds a novel mutation to the spectrum of
FBN1  gene  mutations,  analyzes  the  potential  functional
consequence  of  the  mutation,  and  enriches  the  existing
knowledge  of  genotype–phenotype  correlations  of  Marfan
syndrome.
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Appendix  1.  Primers  used  for  FBN1  amplification.
Summary of the primers used for the amplification of FBN1
exons. Sequences are given in the 5′→3′direction. To access
the data, click or select the words “Appendix 1.” This will
initiate  the  download  of  a  compressed  (pdf)  archive  that
contains the file.
Appendix 2. Clinical details of the patients II:2, III:12,
and  family  member  IV:4.  Each  patient  in  the  family  has
bilateral  ectopia  lentis,  myopia,  arachnodactyly,  and  joint
hypermobility. Only the proband displays abnormalities of the
cardiovascular  system.  Individual  IV:4  appears  normal.
Abbreviations: M: male; F: female; IOL: intraocular lens; AS/
H: arm span/height ratio; +: present; –: absent. N: normal. To
access the data, click or select the words “Appendix 2.” This
will initiate the download of a compressed (pdf) archive that
contains the file.
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